Drug Trial Radar · NCT06732401
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
630
Planned (sponsor's estimate)
Start
Aug 7, 2025
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Dec 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Conditions
- Lung Non-Small Cell Carcinoma
- Stage II Lung Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
CeralasertibDrug
Given PO
Computed TomographyProcedure
Undergo CT scan
DurvalumabBiological
Given IV
Echocardiography TestProcedure
Undergo echocardiography
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free survival (DFS)Time frame: From randomization to the earliest event defined as the first recurrence of non-small cell lung cancer (NSCLC), any new lung cancer or death, up to 10 years
Locations
192 sites in 1 country. Site status is shown where the registry gives one.
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
Tower Cancer Research Foundation
Beverly Hills, California
Cedars-Sinai Medical Center
Los Angeles, California
Cedars-Sinai Cancer - Tarzana
Tarzana, California
Torrance Memorial Physician Network - Cancer Care
Torrance, California
Hartford Hospital
Hartford, Connecticut
Midstate Medical Center
Meriden, Connecticut
The Hospital of Central Connecticut
New Britain, Connecticut
Beebe South Coastal Health Campus
Millville, Delaware
Helen F Graham Cancer Center
Newark, Delaware
Medical Oncology Hematology Consultants PA
Newark, Delaware
Beebe Health Campus
Rehoboth Beach, Delaware
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Emory University Hospital Midtown
Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Emory Saint Joseph's Hospital
Atlanta, Georgia
Emory Decatur Hospital
Decatur, Georgia
Emory Johns Creek Hospital
Johns Creek, Georgia
Saint Luke's Cancer Institute - Boise
Boise, Idaho
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho
Illinois CancerCare-Bloomington
Bloomington, Illinois
Illinois CancerCare-Canton
Canton, Illinois
Illinois CancerCare-Carthage
Carthage, Illinois
Northwestern University
Chicago, Illinois
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois
Decatur Memorial Hospital
Decatur, Illinois
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois
Illinois CancerCare-Dixon
Dixon, Illinois
Crossroads Cancer Center
Effingham, Illinois
Illinois CancerCare-Eureka
Eureka, Illinois
Illinois CancerCare-Galesburg
Galesburg, Illinois
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois
Northwestern Medicine Glenview Outpatient Center
Glenview, Illinois
Showing 40 of 192 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.